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Members of the TNF SuperFamily of ligands (TNFSFs)
have significant potential as immuno-oncology therapeu-
tic agents. The TNFSFs are trimeric membrane proteins
that can be cleaved into soluble single trimers. While
the soluble single trimers can be easily prepared and
studied, they have little or no activity in vivo. This defi-
ciency is caused by the need to cluster their cognate
receptors in the plane of the membrane in order to
induce a supramolecular signaling complex on the cyto-
plasmic side of the plasma membrane. For the TNFSF
ligands, this requires that they be used as many-trimer
multimers that mimic the natural expression of many
trimers on the surface of stimulating cells. To meet this
need, we prepared fusion proteins comprised of the
extracellular domains of TNFSF ligands joined to a nat-
ural protein that provides a multimerization scaffold.
When Acrp30 (a natural serum protein) is used as a
scaffold, the result is a 2-trimer TNFSF ligand product
(MegaLigand™). When surfactant protein D (SPD) is
used as a scaffold, the result is a 4-trimer TNFSF ligand
product (UltraLigand™). Our published studies have
described such multimeric forms of CD40L, OX40L,
GITRL, CD27L/CD70, BAFF, RANKL, and TRAIL and
shown that they are highly active in vitro and in vivo.
As an extension of this work, 4-trimer forms of murine
and human 4-1BBL (CD137L, TNFSF9) were con-
structed and expressed in CHO cells. As a co-stimula-
tory molecule, SPD-4-1BBL (Ultra4-1BBL™) promotes
the proliferation of CD4+ and CD8+ T cells in vitro.
Given the interest in 4-1BB (CD137) as a marker of
therapeutically effective tumor-infiltrating lymphocytes
(TILs), SPD-4-1BBL will be a useful growth factor for
TIL manufacturing and T cell culturing in general.
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